Evidence map›Paper›PMID 40075667›Full record

ArticleCancers2025

Evaluation of an

Melanie Winter, Silvana Ebner, Nina Scheuber, Falko Schulze, Maximilian N Kinzler, Dirk Walter, Peter J Wild

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Melanie WinterDr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Silvana EbnerUniversity Hospital Frankfurt MVZ GmbH, 60590 Frankfurt, Germany.
Nina ScheuberDr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Falko SchulzeDr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Maximilian N KinzlerMedical Clinic 1, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0003-2378-1455
Dirk WalterMedical Clinic 1, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.
Peter J WildDr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCholangiocarcinoma, a malignancy originating from the bile ducts, poses significant treatment challenges due to its typically late diagnosis and limited therapeutic options. However, recent advances in molecular genetics enable more personalized treatment approaches. A notable breakthrough in this context is the identification of isocitrate dehydrogenase (IDH) mutations, particularly

methodsUnder this aspect, a set of cholangiocarcinomas was tested using the Idylla™ platform regarding the respective recommended guidelines and standards of DIN EN ISO:17020 and DIN EN ISO:15198.

resultsOverall, 25 clinically diagnosed intrahepatic cholangiocarcinomas or Adeno-CUPs were analyzed.

conclusionsIdylla

Indexed as

BiocartischolangiocarcinomaGenexusIDH1IDH2Idylla™molecularOncomine Comprehensive Assay v3 GXpathology

Identifiers

PMID40075667
PMCPMC11898960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.